1. GPCR/G Protein
  2. Bradykinin Receptor
  3. Bradykinin

Bradykinin 

Cat. No.: HY-P0206 Purity: 99.86%
Handling Instructions

Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Bradykinin Chemical Structure

Bradykinin Chemical Structure

CAS No. : 58-82-2

Size Price Stock Quantity
5 mg USD 72 In-stock
Estimated Time of Arrival: December 31
10 mg USD 108 In-stock
Estimated Time of Arrival: December 31
25 mg USD 180 In-stock
Estimated Time of Arrival: December 31
50 mg USD 312 In-stock
Estimated Time of Arrival: December 31
100 mg USD 552 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.

In Vitro

Bradykinin is a potent vasodilator peptide that exerts its vasodilatory action through stimulation of specific endothelial B2 receptors, thereby causing the release of prostacyclin, NO, and EDHF[1]. Bradykinin has been reported to be involved in the progression of many types of cancer. Bradykinin treatment promotes the invasion and migration of colorectal cancer cells. Bradykinin treatment stimulates ERK1/2 activation and IL-6 production[2]. Exogenous bradykinin markedly inhibits TF expression in mRNA and protein level induced by LPS in a dose-dependent manner. The NO synthase antagonist L-NAME and PI3K inhibitor LY294002 dramatically abolish the inhibitory effects of bradykinin on tissue factor expression[3].

In Vivo

Application of 1 μM bradykinin to the ovary produces significant decreases in heart rate and mean arterial pressure. In vagotomized animals, application of 1 μM bradykinin to the ovary produces bradycardia and hypotension similar to the responses evoked when vagal innervation is intact[4]. Vascular bradykinin can improve pancreatic microcirculation and hemorheology in rats with severe acute pancreatitis. The pancreatic microcirculatory blood flow volume and velocity in the vascular bradykinin treatment group increases gradually after 48 h[5]. PI3K/Akt signaling pathway activation induced by bradykinin administration reduces the activity of GSK-3β and MAPK, and reduces NF-x03BA;B level in the nucleus, thereby inhibiting TF expression. Consistent with this, intraperitoneal injection of C57/BL6 mice with bradykinin also inhibits the thrombus formation induced by ligation of inferior vena cava[3].

Clinical Trial
Molecular Weight

1060.21

Formula

C₅₀H₇₃N₁₅O₁₁

CAS No.

58-82-2

Sequence

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg

Sequence Shortening

RPPGFSPFR

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL (94.32 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.9432 mL 4.7160 mL 9.4321 mL
5 mM 0.1886 mL 0.9432 mL 1.8864 mL
10 mM 0.0943 mL 0.4716 mL 0.9432 mL
*Please refer to the solubility information to select the appropriate solvent.
References
Cell Assay
[2]

SW480 cells are pretreated with different concentrations of bradykinin (0, 0.1, 0.5, 1 μM), and then subjected to invasion and migration assays[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3][4]

Rats: Bradykinin acetate is applied topically to the surface of the ovary with a thin piece of cotton (7×7 mm square) soaked with the solution. After application for 30 s, the cotton is removed. Each of the stimuli is delivered to the animal after observing stabilization of heart rate and mean arterial pressure[4].

Mouse: Mice are randomly divided into 3 groups: Sham, Model and Bradykinin. Before surgical procedure, the mice of bradykinin group are intraperitoneally injected with bradykinin (10 mg/kg/d) once a day for three days. After ligation, the mice receive bradykinin injection for another two days and analgesic therapy is performed using buprenorphine at 0.1 mg/kg body weight for 3 days. The mice in other groups receive equal saline as control[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Purity: 99.86%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

BradykininBradykinin ReceptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
Bradykinin
Cat. No.:
HY-P0206
Quantity:
MCE Japan Authorized Agent: